Skip to Content

Biocytogen Pharmaceuticals (Beijing) Co Ltd Class H 02315

Morningstar Rating
HK$7.47 +0.19 (2.61%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

02315 is trading within a range we consider fairly valued.
Price
HK$7.29
Fair Value
HK$25.70
Uncertainty
Very High
1-Star Price
HK$53.96
5-Star Price
HK$1.77
Economic Moat
Tvvv
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 02315 is a good fit for your portfolio.

News

Trading Information

Previous Close Price
HK$7.28
Day Range
HK$7.307.49
52-Week Range
HK$5.7420.80
Bid/Ask
HK$7.39 / HK$7.47
Market Cap
HK$2.97 Bil
Volume/Avg
35,500 / 117,782

Key Statistics

Price/Earnings (Normalized)
Price/Sales
3.66
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.31%

Company Profile

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
1,066

Comparables

Valuation

Metric
02315
ALVR
09995
Price/Earnings (Normalized)
Price/Book Value
3.350.752.29
Price/Sales
3.667.22
Price/Cash Flow
Price/Earnings
02315
ALVR
09995

Financial Strength

Metric
02315
ALVR
09995
Quick Ratio
0.9618.381.04
Current Ratio
1.2518.481.96
Interest Coverage
−2.91−65.67
Quick Ratio
02315
ALVR
09995

Profitability

Metric
02315
ALVR
09995
Return on Assets (Normalized)
−13.53%−52.15%−24.32%
Return on Equity (Normalized)
−37.28%−65.46%−33.25%
Return on Invested Capital (Normalized)
−20.22%−59.04%−28.59%
Return on Assets
02315
ALVR
09995
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
WqlygxxzfVwbt$632.3 Bil
Vertex Pharmaceuticals Inc
VRTX
CkfrqhdVxgjcpt$126.7 Bil
Regeneron Pharmaceuticals Inc
REGN
PnrgpmqZgzzt$119.2 Bil
Moderna Inc
MRNA
YjnvysbxxRfg$46.6 Bil
Alnylam Pharmaceuticals Inc
ALNY
KkyphnlQyvcznt$32.4 Bil
argenx SE ADR
ARGX
FfxmhcltGfzbm$27.6 Bil
BioNTech SE ADR
BNTX
ZsczcwvxSqynx$20.3 Bil
Biomarin Pharmaceutical Inc
BMRN
NrdfjbmrXhkgzrf$16.1 Bil
United Therapeutics Corp
UTHR
VxnjnytfZqs$14.5 Bil
Incyte Corp
INCY
CmphnwdFjmnc$12.7 Bil

Sponsor Center